The prevalence of malnutrition and the evolution of nutritional status in patients with moderate to severe forms of Crohn’s disease treated with Infliximab
| Autor: | Roxana Vadan, Liliana Gheorghe, Cristian Gheorghe, Alexandrina Constantinescu |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Nutritional Status Weight Gain Critical Care and Intensive Care Medicine Body Mass Index Young Adult Crohn Disease Gastrointestinal Agents Internal medicine medicine Humans Prospective Studies Prospective cohort study Analysis of Variance Crohn's disease Nutrition and Dietetics medicine.diagnostic_test business.industry Malnutrition Antibodies Monoclonal Middle Aged medicine.disease Crohn's Disease Activity Index Infliximab Surgery Treatment Outcome Erythrocyte sedimentation rate Female medicine.symptom business Weight gain Body mass index medicine.drug |
| Zdroj: | Clinical Nutrition. 30:86-91 |
| ISSN: | 0261-5614 |
| DOI: | 10.1016/j.clnu.2010.07.019 |
| Popis: | Summary Background & aims Malnutrition is variably encountered in adult patients with Crohn’s disease. We evaluated the nutritional status at the beginning and during Infliximab treatment in patients with Crohn’s disease. Methods Patients with moderate/severe flares of disease treated with Infliximab for induction and maintenance of remission were included in a prospective observational study. Body Mass Index and Nutritional Risk Index were calculated in each patient at 0, 6 weeks and than every 8 weeks for one year. Results From 30 patients treated with Infliximab 59.3% had low BMI, 35.7% being undernourished. The severity of Crohn’s disease did not correlate with low BMI but did correlate with Nutritional Risk Index (p = 0.001). In all patients that responded to Infliximab treatment progressive weight gain was observed, all but one patient reaching normal BMI after one year. Mean weight gain was significantly more elevated (p = 0.001) and time needed to reach normal BMI was longer in the undernutrition group (p = 0.01). Clinical remission was the principal factor associated with weight gain (p = 0.001), while there was no influence of endoscopic remission on nutritional status. Conclusions In patients with moderate/severe forms of Crohn’s disease malnutrition is frequently encountered. Induction and maintenance treatment with Infliximab determines weight gain and corrects malnutrition in all patients with clinical remission. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect